Aequs shares hit a 52-week high of ₹193.65, rising over 13% intraday and extending a 36% six-session rally, as the contract manufacturer disclosed a ₹10 crore rights-issue investment in its consumer products subsidiary.

1mo ago · 3 min · Markets

PolyPeptide has drawn buyout interest as its operational turnaround gains traction with potential acquirers. The development signals improving confidence in the contract peptide manufacturer's stability, with the peptide CDMO sector under heightened strategic attention due to GLP-1 drug demand. Whether a formal sale pr

2mo ago · 1 min · Business